Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.

The pharmacogenomics journal - 24 Apr 2026

Coerts Daniël T, Smith-Apeldoorn Sanne Y, Oude Nijhuis Jérôme C, van Schaik Ron H N, Tamminga Wim J, Touw Daan J, Veraart Jolien K E, Schoevers Robert A, van Dalfsen Jens H

Abstract excerpt

Oral esketamine displays therapeutic potential for treatment-resistant depression. However, treatment is complicated by a low and variable bioavailability. Genetic polymorphisms in the cytochrome P450 (CYP) enzymes responsible for esketamine's metabolism may influence bioavailability. In a subsample of patients included in a placebo-controlled trial investigating repeated, low dose oral esketamine (N = 18), blood...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Biological Availability

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to Cytochrome P-450 CYP3A

Share to Cytochrome P-450 Enzyme System

Share to Genotype

Share to Polymorphism, Genetic

Share to Polymorphism, Single Nucleotide

Source

Identifiers

PMID: 42031731
DOI: 10.1038/s41397-026-00405-5

Genes

CYP2B6
CYP3A4
CYP3A5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.PMID 42031731Read ↗

ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.Semantic proximity Read ↗

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors.Semantic proximity Read ↗

[Characterisation of selected molecular mechanisms influencing pharmacokinetics and pharmacodynamics of antidepressants].Semantic proximity Read ↗

Exploring the role of drug-metabolising enzymes in antidepressant side effects.Semantic proximity Read ↗

The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression.Semantic proximity Read ↗

ABCB1 C3435T, G2677T/A and C1236T variants have no effect in eslicarbazepine pharmacokinetics.Semantic proximity Read ↗

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extensionSemantic proximity Read ↗

A Prospective Study of Serotonin and Norepinephrine Transporter Genes and the Response to Desvenlafaxine Over 8 Weeks in Major Depressive Disorder.Semantic proximity Read ↗

Doxepin Drug-Drug and Drug-Gene Interactions: Clinical Implications and Mechanistic InsightsSemantic proximity Read ↗

Influence of Genetic Polymorphisms on the Pharmacokinetics of Trazodone Hydrochloride: A Scoping Review and Future Perspective.Semantic proximity Read ↗

Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.Semantic proximity Read ↗

The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.